Nine months 2011: Dräger increases order intake and earnings

Thursday, 03. November 2011 07:30
Drägerwerk AG & Co. KGaA /
Nine months 2011: Dräger increases order intake and earnings
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

* Order intake grows by 7.8 percent
* EBIT margin reaches 9.0 percent
* Equity ratio continues to rises to 34.7 percent
* Sales reorganization resolved
* Personnel changes
* Outlook 2011 and 2012

Lübeck - Drägerwerk AG & Co. KGaA's order intake and earnings increased in the
first nine months of 2011. Stefan Dräger, Chairman of the Executive Board of
Drägerwerk Verwaltungs AG: "We closed our third quarter with positive figures
and in doing so, we have laid the foundations for performing better than
expected at the beginning of the year."

Order intake: Up 7.8 percent
Strong growth of 7.8 percent (net of currency effects) meant that the order
intake in the first nine months of 2011 (EUR 1.68 billion) was significantly
higher than in the previous year (9 months 2010: EUR 1.57 billion). Net sales in
the first nine months of 2011 rose by 1.8 percent (net of currency effects) to
EUR 1.56 billion (9 months 2010: EUR 1.54 billion). Both divisions developed
differently: The safety division profited in particular from an upturn in demand
from the industrial sector. Net sales in the first nine months of 2011 were
therefore up 9.7 percent (net of currency effects) year-on-year. Net sales in
the medical division, on the other hand, went down by 1.8 percent (net of
currency effects) in the same period. Similar to the second quarter of 2011, the
decline is mainly due to a large order from Brazil in the previous year.

Earnings: Gross profit up, EBIT margin reaches 9.0 percent
Dräger increased its gross earnings by EUR 26.7 million to EUR 776.1 million in
the first nine months of 2011. The gross margin consequently rose to 50.2
percent (9 months 2010: 49.3 percent), which was mainly due to net sales growth,
an improved product mix as well as a positive earnings contribution from deep
sea diving projects in the safety division. In the first nine months of 2011,
Dräger achieved total EBIT of EUR 139.7 million (9 months 2010: EUR 136.7
million). The EBIT margin therefore came to 9.0 percent (9 months 2010: 8.9
percent). Functional costs went up by around 6 percent year-on-year during the
reporting period, mainly on account of a scheduled rise in investments in
research and development, the ongoing IT optimization and higher expenses for
additional sales activities. The financial result increased by EUR 12.4 million.

Net assets: Equity ratio continues to rise
Dräger Group's equity rose by EUR 35.7 million to EUR 672.3 million in the first
nine months of 2011. The equity ratio therefore went up to 34.7 percent
(December 31, 2010: 32.2 percent). Stefan Dräger: "Our solid company financing
allows us, on the one hand, to invest in our future, and on the other, not have
to reduce our high level of security. We are well equipped with our equity
ratio, low net debt, extensive free credit lines, an improved risk early warning
system and greater flexibility."

Sales reorganization resolved
The Executive Board of Drägerwerk Verwaltungs AG resolved to pool the sales
functions of the medical and safety divisions in all regions under one operating
manager each as from 2012 to further increase the Company's profitability. The
objective of this measure is for Dräger to achieve an even greater
differentiation of individual markets and improve the use of the Company-wide
infrastructure. Andreas Frahm will assume the position of global sales manager.
He has been working in various management positions within the Company for many
years and is currently Regional Manager for Asia / Pacific in the medical
division.

Personnel changes
Dr. Carla Kriwet, Dräger Executive Board member responsible for Sales and
Marketing, will leave the Company at the end of the year by mutual consent. Both
parties agreed to maintain secrecy about the reasons for her resignation. Dräger
will therefore have to change its plans of reorganizing its marketing function
and postpone them until 2013.
Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG: "I
regret that both our expectations and hopes in our cooperation have not come to
fruition. I nevertheless would like to expressly thank Dr. Kriwet for her
achievements in the past months. The Supervisory and Executive Boards wish her
all the best for the future."

There will also be a change in the medical division: Dr. Christian Hauer, member
of the Executive Team of Drägerwerk AG & Co KGaA and General Manager of Dräger
Medical GmbH will leave the Company at his own request in February 2012 to take
on new professional challenges.
"The departure of Dr. Hauer, an extremely experienced long-standing manager, is
a loss to us all. He joined the highest ranks of our Company through his
excellent performance. We wish him all the very best and much success for his
future," commented Stefan Dräger.

Outlook: 2011 and 2012 forecast
Dräger continues to anticipate that order intake will grow at least as fast as
the entire global economy in fiscal year 2011. Given the IMF's adjusted global
economic growth forecast in September 2011 of +4.0 percent, Dräger expects to
see similar growth in its order intake. Net sales growth in the Group in 2011 is
expected to be one to two percentage points down on order intake growth as net
sales in 2010 benefited from above-average order intake in the fourth quarter of
2009. Dräger now expects to be able to achieve the upper region of the Group
EBIT margin between 8.0 percent 9.5 percent, which had been forecast in July.
Dräger anticipates that it will continue to grow at least as fast as the entire
global economy in 2012 (IMF September 2011 estimate: +4.0 percent). However,
costs for sales, research and development and IT are expected to rise more
steeply than net sales in 2012. The Company will now implement those measures
necessary for realizing the new sales structure that were originally planned for
2011 in 2012 instead. Dräger will also invest further in product development to
ensure its competitive position in the long term. In addition, the EU Directives
RoHS[1]/REACH[2], which require for the use of certain materials to be
restricted as from 2014, make it necessary to invest further in research and
development. Dräger will also continue to renew its IT infrastructure. The
Company once again forecasts a Group EBIT margin between 8.0 percent and 9.5
percent for fiscal year 2012. This assumption is based on stable market
developments and takes into account the costs for sales, research and
development and IT described above.

In the medium term, the new structure will significantly reduce sales expenses
and tap into additional growth prospects. Overall, Dräger expects to achieve at
least one percentage point in savings regarding the relative marketing and
selling expenses by the end of 2014. The Company also plans to continue to grow
faster than the market and achieve a minimum EBIT margin of 10 percent in the
medium term.

This is based on the assumption of a stabilizing economy in Europe, continued
economic recovery in North America, sustained market growth in developing
countries and stable exchange rates. It must be noted that global uncertainty
factors further increased, making an exact forecast more difficult. This also
applies to the increased volatility of exchange rates expected by the Executive
Board.


[1] EU Directive "Restriction of the use of certain hazardous substances in
electrical and electronic equipment"
[2] EU Directive "Registration, Evaluation and Restriction of Chemicals"


Key figures for the first nine months of 2011 (in EUR million)
+----------------------+-------+-------+-------+-------+-------+---------------+
|   | Third | Third | Nine | Nine |Change |Net of currency|
| |quarter|quarter|months |months | | effects |
| | 2011 | 2010 | 2011 | 2010 | | |
+----------------------+-------+-------+-------+-------+-------+---------------+
|Order intake | 570.7| 519.5|1,679.7|1,568.4| +7.1 %| +7.8 %|
+----------------------+-------+-------+-------+-------+-------+---------------+
|Medical division | 383.6| 357.5|1,097.5|1,056.3| +3.9 %| +5.0 %|
+----------------------+-------+-------+-------+-------+-------+---------------+
|Safety division | 194.6| 167.7| 604.8| 532.8|+13.5 %| +13.8 %|
+----------------------+-------+-------+-------+-------+-------+---------------+
|  |  |  |  |  |  |  |
+----------------------+-------+-------+-------+-------+-------+---------------+
|Net sales | 524.0| 525.3|1,557.3|1,542.0| +1.0 %| +1.8 %|
+----------------------+-------+-------+-------+-------+-------+---------------+
|Medical division | 335.2| 351,7| 998.2|1,028.9| -3.0 %| -1.8 %|
+----------------------+-------+-------+-------+-------+-------+---------------+
|Safety division | 196.2| 178.6| 581.3| 531.6| +9.4 %| +9.7 %|
+----------------------+-------+-------+-------+-------+-------+---------------+
|  |  |  |  |  |  |  |
+----------------------+-------+-------+-------+-------+-------+---------------+
|EBIT[1] | 45.2| 34.1| 139.7| 136.7| +2.2 %|  |
+----------------------+-------+-------+-------+-------+-------+---------------+
|Medical division | 37.9| 35.2| 107.8| 128.2|-15.9 %|  |
+----------------------+-------+-------+-------+-------+-------+---------------+
|Safety division | 20.9| 17.8| 66.7| 47.1|+41.5 %|  |
+----------------------+-------+-------+-------+-------+-------+---------------+
|  |  |  |  |  |  |  |
+----------------------+-------+-------+-------+-------+-------+---------------+
|EBIT margin | 8.6 %| 6.5 %| 9.0 %| 8.9 %|  |  |
+----------------------+-------+-------+-------+-------+-------+---------------+
|Earnings after income | | | | | | |
|taxes | 25.6| 14.3| 79.3| 70.2|+13,0 %|  |
+----------------------+-------+-------+-------+-------+-------+---------------+
|EPS[2] preferred share| 1.36| 0.75| 4.18| 4.27|  |  |
+----------------------+-------+-------+-------+-------+-------+---------------+
|EPS[2] common share | 1.34| 0.73| 4.13| 4.22|  |  |
+----------------------+-------+-------+-------+-------+-------+---------------+

[1] EBIT = Earnings before interest and taxes
[2] EPS = Earnings per share (in €)


Disclaimer
This press release contains forward-looking statements regarding the future
development of the Dräger Group. These forward-looking statements are based on
the current expectations, presumptions, and forecasts of the Executive Board as
well as the information available to it to date and have been prepared to the
best of its knowledge and belief. No guarantee or liability for the occurrence
of the future developments and results specified can be assumed in respect of
such forward-looking statements. Rather, the future developments and results are
dependent on a number of factors. They entail risks and uncertainties beyond the
Company's control and are based on assumptions which could prove to be
incorrect. Notwithstanding any legal requirements to adjust forecasts, Dräger
does not assume any obligation to update the forward-looking statements
contained in this report. You will find all important financial dates on the
Company website atwww.draeger.com under Investor Center/Financial Calendar.


Contact

Corporate Communications:
Melanie Kamann
Phone: +49 451 882-3998
melanie.kamann@draeger.com

Investor Relations:
Vanina Hoffmann
Phone: +49 451 882-2685
vanina.hoffmann@draeger.com


Drägerwerk AG & Co. KGaA
Moislinger Allee 53 - 55
23558 Lübeck, Germany
www.draeger.com

--- End of Message ---

Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55 Lübeck Germany


Listed: Freiverkehr in Börse Stuttgart,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse,
Regulierter Markt in Bayerische Börse München,
Regulierter Markt in Börse Berlin,
Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,
Regulierter Markt in Börse Düsseldorf,
Regulierter Markt in Niedersächsische Börse zu Hannover;


Press release (PDF):
http://hugin.info/135701/R/1560406/482762.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

[HUG#1560406]
Related Links: Drägerwerk AG & Co. KGaA
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.